FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					

hours per response..

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(I I III OI I J	pe Response	- /													
	. Name and Address of Reporting Person *		2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X_ Director 10% Owner						
	RUM THE	(First) ERAPEUTICS AM COURT, FL	(Middle) . 1, LEESON	3. Date of Earliest Transaction (Month/Day/Year) 06/15/2022			Officer (give	title below)	Other (specify below)					
DUBLIN	1212	(Street)		4. If Amendment, Date Original			ginal Filed(al Filed(Month/Day/Year)			6. Individual or Joint/Group FilingCheck Applicable Line)X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(Cit		(State)	(Zip)	Table I - Non-Derivative Securities Acq			es Acquire	uired, Disposed of, or Beneficially Owned							
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year	r) any	emed ion Date, i /Day/Year	Code (Instr.		4. Securit (A) or Dis (Instr. 3, 4)	sposed o	of (D) Ow Tra	Amount of S yned Followi ansaction(s) str. 3 and 4)		Or Fo Di or (I)	wnership of orm: Be rect (D) Ov Indirect (Ir	eneficial wnership
Reminder:	Report on a	separate line for each	n class of securities b	peneficiall	ly owned o	irectly o	or indirectly	·.							
Reminder:	Report on a	separate line for each		- Derivat	ive Secur	ties Acc	Perso in this a curr	ons who ins form are rently val	e not re lid OME or Bene	equired to 3 control : ficially Ow	respond (number.		on contained form display		74 (9-02)
			Table II	- Derivat (e.g., pu	tive Secur	ties Acc	Perso in this a curi quired, Dis s, options,	ons who it is form are rently value of, convertible	e not re lid OME or Bene le securi	equired to 3 control ficially Ow ties)	respond unumber.	unless the	form display	5	, ,
	2. Conversion	3. Transaction	Table II 3A. Deemed Execution Date, if	- Derivat (e.g., pu 4. Transacti Code	its, calls, v 5. Nui ion Derivi Secur Acqui	ties Accordants mber of attive ties red (A) posed of	Persocin this a curred, Diss, options, of the Expiration (Month/II)	ons who is form are ently value of, convertible entry entry and the entry entr	e not re lid OME or Bene le securi	equired to 3 control ficially Ow ties)	orespond unumber. wned d Amount ying	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	11. Natur
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II 3A. Deemed Execution Date, if any	- Derivat (e.g., pu 4. Transacti Code	5. Nur Jerive Secur Acqui or Dis (D) (Instr.	nber of titive ties red (A) posed of 3, 4,	Perso in this a curr quired, Dis s, options, of the Expiratio (Month/I)	posed of, convertible converti	re not re lid OME or Bene le securi	ficially Owities) 7. Title an of Underly Securities	orespond unumber. wned d Amount ying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirec Beneficia Ownershi

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
HUNT RONALD C/O ITERUM THERAPEUTICS PLC FITZWILLIAM COURT, FL. 1, LEESON CLOSE DUBLIN 2, L2	X					

Signatures

/s/ Ronald Hunt	06/17/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the shares subject to this option shall vest in full on June 15, 2023

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.